Health · 19 June 2026

CMA wins appeal in Pfizer drug case

NHS medicine costs jumped sharply after price rises for an epilepsy treatment, leading to years of legal action over alleged overcharging. A court has ruled the Competition Appeal Tribunal was wrong to overturn the Competition and Markets Authority’s findings against the drug company and its distributor. Spending on phenytoin sodium rose from about £2.3m a year before 2012 to more than £50m in 2013.

By BriefTea Editorial · 19 June 2026 at 14:29

Reported by City AM · How we write briefs

Get the app

More briefs

HealthMan changes life after doctor warns liver disease could kill him HealthSweetener used in chewing gum and jam linked to strokes and heart attacks HealthMouth cancer rates up a third in UK, often with no obvious cause HealthBox breathing helps calm stress and reduce anxiety, say experts HealthNHS managers warn spiralling costs could disrupt ADHD and autism care HealthThousands of UK women get undiagnosed PTSD after childbirth More health stories → Browse all stories →